Compare

Eli Lilly/$LLY

1D1W1M3M6MYTD1Y5YMAX

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Health
Primary listing
NYSE
Employees
50,000
Headquarters
Indianapolis, United States
Website
www.lilly.com

Eli Lilly Metrics

BasicAdvanced
$1.1T
39.59
$29.79
0.50
$6.69
0.59%

What the Analysts think about Eli Lilly

Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Analyst projections of the future price of Eli Lilly stock.

Bulls say / Bears say

Lilly’s core demand is still running ahead of expectations. Second-quarter revenue rose 48%, Mounjaro sales jumped 91% and Zepbound sales rose 46%, prompting the company to lift 2026 revenue guidance to $85bn–$87bn. (CNBC, Nasdaq)
Foundayo gives Lilly a daily oral GLP-1 product alongside its injectable franchise. Recent phase 3 data showed orforglipron reduced HbA1c more than dapagliflozin, supporting a broader diabetes opportunity and potentially easier access for patients who do not want injections. (The Lancet, CNBC)
Lilly is building follow-on growth before its current blockbusters mature. Positive phase 3 retatrutide data completed the clinical package for planned 2027 filings, while wider approvals for Jaypirca add another potential growth stream outside obesity and diabetes. (Lilly, Nasdaq)
Pricing is already taking a meaningful share of Lilly’s growth. Global realised prices fell 13% in the second quarter, so the bull case depends on volume continuing to rise fast enough to offset discounts, rebates and reimbursement pressure. (Nasdaq, CNBC)
The business is becoming heavily dependent on tirzepatide. Mounjaro and Zepbound generated 64.7% of second-quarter revenue, while Novo Nordisk’s oral Wegovy adds competition that could pressure Lilly’s market share or pricing power. (CNBC, Nasdaq)
Acquisition spending is creating near-term earnings drag. Lilly said $3.03 per share of acquired in-process research and development charges more than offset a $2.78 increase from underlying business growth, leaving 2026 adjusted EPS guidance at $35.50–$36.50. (Nasdaq, Lilly)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.

Eli Lilly Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Eli Lilly Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Eli Lilly News

AllArticlesVideos

Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI

MarketBeat5 days ago

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

Investopedia5 days ago

Lilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug

Barrons1 week ago

Funds containing Eli Lilly

AllEURGBPUSD
Funds
Fund name
Fund size
$LLY weighting
iShares S&P 500 Health Care Sector€IUHE
€125M15.22%
iShares MSCI World Health Care Sector Advanced€CBUF
€606M10.85%
iShares Edge MSCI USA Quality Factor£IUQF
£1.5B3.65%
iShares Edge MSCI World Quality Factor$IWQU
$6.3B2.51%
iShares Edge MSCI World Quality Factor€IS3Q
€5.4B2.51%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.